Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dilshad Ahmed Khan has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Profiling of Acute Myeloid Leukemia in Pakistan: Comprehensive Variant Landscape Revealed by Targeted NGS

    by Rafia Mahmood, Saleem Ahmed Khan, Sadia Ali, Fatima Sharif, Umar Khurshid, Dilshad Ahmed, Eshal Shahzad, Hamid Saeed Malik, Naghmi Asif, Sidrah Jahangir

    Acute myeloid leukemia (AML) is a heterogeneous malignancy, with clonal complexity and somatic mutations critically influencing prognosis and treatment. While global genomic profiling efforts have revolutionized AML classification and risk stratification, the molecular landscape in Pakistani patients remains underexplored. Our aim is to perform targeted next-generation sequencing (NGS) for somatic mutational profiling of newly diagnosed AML patients in Pakistan. This prospective study was conducted at the Armed Forces Institute of Pathology, Pakistan, from January 2021 to January 2026. Among 104 patients, 204 somatic variants were identified (mean: 1.96 variants/patient), predominantly single-nucleotide variants (49.5%). Missense mutations (38.2%) were most common, with enriched transitions (Ti/Tv: 1.27:1). Frequently mutated genes included TP53 (22.1%), KIT (9.8%), CEBPA (8.8%), and NRAS (5.9%). Cell-signaling genes (30.4%) and tumor suppressor genes (27.0%) were the most affected functional groups. Co-mutation analysis showed clustering led by DNMT3A–IDH1 co-occurrence (ρ ≈ 0.43). DNA-methylation alterations frequently co-occurred with tumor suppressors (OR ≈ 4.6, p = 0.007), transcription factors (OR ≈ 3.9, p = 0.023), and NPM1 (ρ = 0.32). This study provides the first comprehensive genomic map of Pakistani AML patients, revealing unique mutational signatures. The findings lay the groundwork for population-specific precision oncology in low- and middle-income countries.


  • Open Access

    Circulating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study

    by Sumbal Nida, Dilshad Ahmed Khan, Muhammad Amjad Pervez, Nayyar Chaudhry, Mohammad Qaiser Alam Khan, Alveena Younas

    Metabolic dysfunction-associated fatty liver disease (MAFLD) comprises phenotypic subgroups, including type-2 diabetes-associated MAFLD (T2D-MAFLD), obesity-associated MAFLD (OB-MAFLD), and lean MAFLD (L-MAFLD). Emerging evidence indicates that dysregulation of miRNAs plays a key role in MAFLD pathogenesis and progression. This study evaluated the diagnostic accuracy of a plasma miRNA-based signature as a non-invasive biomarker for early detection and phenotypic stratification of MAFLD. A total of 393 MAFLD patients and 109 healthy controls were enrolled. Plasma expression of miR-122, miR-103a, miR-222, miR-15a, miR-34a, miR-192, miR-197, and miR-99a was quantified using Reverse transcription polymerase chain reaction. Compared to controls, MAFLD patients exhibited significant upregulation of miR-122, miR-103a, miR-222, miR-15a, and miR-34a, alongside downregulation of miR-197 and miR-99a. Multinomial logistic regression revealed phenotype-specific associations: miR-103a, miR-34a, and miR-197 with T2D-MAFLD; miR-122, miR-222, and miR-99a with OB-MAFLD; and miR-15a with L-MAFLD. Receiver operating characteristic analysis demonstrated highest individual diagnostic accuracy for miR-197 in T2D-MAFLD (AUC = 0.784), miR-99a in OB-MAFLD (AUC = 0.869), and miR-15a in L-MAFLD (AUC = 0.776). Integrating combined miRNA panels with biochemical markers further improved diagnostic performance and clinical utility, achieving high positive and negative predictive values. In conclusion, plasma miRNA signatures enable phenotype-specific discrimination of MAFLD subtypes and may serve as promising non-invasive tools pending multi-center validation.

  • Open Access

    Diagnostic and Prognostic Implications of FGFR3, TP53 Mutation and Urinary Biomarkers in Urothelial Carcinoma in Pakistani Cohort

    by Muhammad Asif, Faiza Abdul Rashid, Saima Shakil Malik, Dilshad Ahmed Khan, Muhammad Tanveer Sajid, Asma Gul, Muhammad Tahir Khadim

    Background: Urothelial carcinoma (UC) presents with clinically heterogeneous disease. There is an emerging need to explore the prognosis of non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Therefore, we aimed to explore the prognostic value of FGFR3 and TP53 mutations and protein expression and to investigate the diagnostic utility of urine cytology and Xpert bladder cancer monitor (BCM) assay in UC. Materials and Methods: A prospective cross-sectional study was conducted in a cohort of 73 Pakistani patients. Cystoscopy, biopsy, tissue diagnosis, UC grade, and stage followed by immunohistochemistry (IHC) and genotyping were recorded. Voided urine samples were also collected for urine cytology and Xpert BCM. Statistical analysis was performed using SPSS version 26.0. A p-value ≤ 0.05 was considered statistically significant. Results: In our selected patients, the majority were males who had smoking history and the common symptom was hematuria. Our findings suggest FGFR3 IHC expression is strongly linked to low-grade NMBIC (p ≤ 0.01). p53 IHC expression supports the findings of the UC grade (p ≤ 0.01). A highly significant association (p < 0.001) was observed between FGFR3 protein expression and underlying mutations. Pro72Arg polymorphism (p = 0.04) was found to be significantly correlated with p53 IHC findings. While comparing cystoscopy with cytology and Xpert BCM, the sensitivity was found to be 85.7% and 58.5%, respectively. Conclusions: The integrated approach of IHC with genotyping could improve risk stratification and guide personalized management strategies. Moreover, as cytology is less sensitive to diagnose UC, especially low-grade tumours, Xpert BCM can be used as a promising diagnostic test for both primary and recurrent BC settings.


  • AI-CADS: An Artificial Intelligence based framework for automatic early detection and severity evaluation of coronary artery disease

    by Muhammad Sajid, Ali Hassan, Dilshad Ahmed Khan, Shoab Ahmed Khan, Asim Dilawar Bakhshi, Sayed Tanveer Abbas Gilani, Muhammad Usman Akram, Mustansar Ali Ghazanfar


  • Open Access

    Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression

    by Muhammad Amjad Pervez, Dilshad Ahmed Khan, Sayed Tanveer Abbas Gilani, Safia Fatima, Aamir Ijaz, Sumbal Nida

    MicroRNAs (miRNAs) play a key role in the regulation of genes for normal metabolism in the liver. Dysregulation of miRNAs is involved in the development and progression of non-alcoholic fatty liver disease (NAFLD). We aimed to explore changes in circulating miRNA expression in response to delta-tocotrienol (δT3) and alpha-tocopherol (αTF) supplementation and correlate them with relevant biochemical markers in patients with NAFLD. In total, 100 patients with NAFLD were randomized to either receive δT3 (n = 50) 300 mg or αTF (n = 50) 268 mg twice/day for 48 weeks. Plasma expression of miRNA-122, -21, -103a-2, -421, -375 and -34a were determined at baseline, 24 and 48 weeks of intervention using RT-qPCR. Both δT3 and αTF significantly downregulated expression of miRNA-122, -21, -103a-2, -421, -375 and -34a. Moreover, δT3 was more effective than αTF in reducing expression of miRNA-375 and -34a. A significant correlation was observed between miRNA expression and biochemical markers of hepatic steatosis, insulin resistance (IR), oxidative stress (OS), inflammation and apoptosis. δT3 and αTF exert hepato-protective effects by downregulating miRNAs involved in hepatic steatosis, IR, OS, inflammation and apoptosis in patients with NAFLD. Furthermore, δT3 has more pronounced effects than αTF in reducing miR-375 and miR-34a, which are linked to regulation of inflammation and apoptosis.


  • Early Diagnosis of Coronary Artery Disease by Inflammatory Biomarkers of Atherosclerosis in Patients with Angina

    by Sayed Tanveer Abbas Gilani, Dilshad Ahmed Khan, Amer Rauf, Zujaja Hina Haroon, Kumail Abbas Khan, Faheem Ul Hassan

    Early diagnosis of coronary artery disease (CAD) in patients with chest pain is a challenge. Currently diagnosis of CAD is confirmed by coronary angiography, which is invasive and not easily available in developing countries. Therefore, it is imperative to establish noninvasive biomarker for early diagnosis of CAD in patients with angina and determine the diagnostic accuracy of inflammatory biomarkers of atherosclerosis in comparison to angiography and correlate with severity of CAD in patients with angina. Diagnostic accuracy study was carried out in tertiary care hospitals, Rawalpindi, Pakistan. Total of 58 patients aged 55.24 ± 11.61 years, with chest pain and troponin-I −ve, having coronary artery stenosis ≥50% were included as cases of CAD and 55 subjects having stenosis P < 0.05) high area under curve (95% confidence interval) with sensitivity and specificity of NF-κB 0.76 (0.65–0.85), 73% and 65%; TNF-α 0.72 (0.61–0.81), 71% and 69%; IL-6 0.62 (0.52–0.71), 64% and 53% and hs-CRP 0.62 (0.52–0.71), and 53% and 56% in CAD patients compared to controls. There was significant positive correlation between NF-κB ( r = 0.44), TNF-α ( r = 0.37), IL-6 ( r = 0.23), and hs-CRP ( r = 0.23) with severity of CAD by Gensini score. The inflammatory biomarkers, especially NF-κB and TNF-α, have highest diagnostic accuracy and indicate severity of atherosclerosis in patients with angina. These markers may be used as noninvasive biomarkers to exclude healthy individuals before undergoing angiography.


  • Effects of delta-tocotrienol supplementation on glycaemic control in individuals with prediabetes — a randomized controlled study

    by Farhana Suleman, Dilshad Ahmed Khan, Muhammad Amjad Pervez, Mohammad Aamir

    Objective: To study the effects of delta-tocotrienol on glycaemic control parameters in individuals with pre-diabetes. Method: The randomised control trial was conducted at the Armed Forces Institute of Pathology, Rawalpindi, Pakistan, from July 15 to November 15, 2019, and comprised individuals aged 18-60 years having fasting plasma glucose of 5.6 to 6.9mmol/L or glycosylated haemoglobin of 5.7 to 6.4%. They were randomised into group A receiving 300mg delta-tocotrienol and group B receiving a placebo once daily for 12 weeks. Weight, height, waist circumference, fasting plasma glucose, insulin and glycosylated haemoglobin were measured at the beginning and end of the trial to assess any change. Body mass index and homeostatic model assessment-insulin resistance were also calculated. Data was analysed using SPSS 21. Results: Of the 77participants, 40(52%) were in group A and 37(48%) in group B. Group A showed significantly greater reduction in terms of fasting plasma glucose, glycosylated haemoglobin, insulin and homeostatic model assessment-insulin resistance index (p?0.001) post-intervention. Conclusion: Delta-tocotrienol supplementation was found to have a significant effect in improving glycaemic control parameters in persons with pre-diabetes. Futures larger scale clinical trials are needed to confirm these findings. Continuous...


  • Open Access

    Challenges in Hemoglobin A1C Measurement in 183 Patients with Diabetes having Hemoglobin Variants and Chemically Modified Derivatives

    by Dilshad Ahmed Khan, Sumbal Nida

    Diabetes is considered as one of the most common metabolic disorder. It has challenged in terms of diagnosis,monitoring and management in the patients with type-2 diabetes. Glycosylated Hemoglobin (HbA1c) hasrecently been validated for the diagnosis diabetes in non-fasting condition, long term blood glycose monitoringand also predicting its complications in the patients. National Glycohemoglobin Standardization Program andInternational Federation of Clinical chemistry have been collaborating for the harmonization of HbA1cmethods and directing the laboratories to maintain strict quality goals. However, standardization of variousHbA1c methods being used worldwide still needs consideration especially in diabetic patients havinghemoglobin variants. The main objectives are to review HbA1c methods and address challenges in itsmeasurement methodology for the patients with diabetes mellitus having hemoglobin variants or chemicallymodified derivatives. Thus, to provide guidance to the clinical pathologist for selection of appropriate methodfor their laboratories.